FEATURED SEARCH: diabetes
Comorbid Type 2 diabetes is associated with a poor outlook for patients who have systolic heart failure (SHF), but many doctors are apprehensive about treating SHF with beta blockers in this population because some studies suggest they may worsen glycemic control or lipid biomarkers. These researchers revisit the question in an observational study, concluding that beta blockers do not increase these risks and should not be withheld from people who have both SHF and type 2 diabetes.
RESULT: Beta Blocker Use in Subjects with Type 2 Diabetes Mellitus and Systolic Heart Failure Does Not Worsen Glycemic Control
Cardiovascular Diabetology | Feb 14, 2012 (FREE FULL TEXT)
Given concerns about the possible cardiovascular effects of antidiabetic agents, the manufacturer of the dipeptylpeptidase-4 inhibitor saxaglyptin (Onglyza) looked at data from Phase II and Phase III trials to assess the effects of glycemic control on cardiovascular risk factors. The results were encouraging. Trials to determine if Saxagliptin truly relieves the risk of cardiovascular disease disease are ongoing.
RESULT: Saxagliptin for the Treatment of Type 2 Diabetes Mellitus: Assessing Cardiovascular Data
Cardiovascular Diabetology | Jan 16, 2012 (FREE FULL TEXT)